Sibutramine
Introduction
Sibutramine is a pharmacological agent that functions as a serotonin and norepinephrine reuptake inhibitor. Originally designed for the treatment of depression, it was later repurposed and used primarily for the short- and long-term management of obesity. However, in 2010, its usage was withdrawn due to an observed increased risk of cardiovascular events.
Mechanism of Action
Sibutramine, chemically referred to as si bue' tra meen, belongs to the beta-phenylethylamine class of compounds. It acts by inhibiting the reuptake of two neurotransmitters in the brain: serotonin and norepinephrine. While it was initially developed to act as an antidepressant, sibutramine exhibited a minimal therapeutic effect on depression. However, an unintended consequence of its administration was weight loss, which researchers linked to decreased appetite and a subsequent reduction in caloric intake.
Relationship with Liver Toxicity
In comprehensive clinical trials, the administration of sibutramine did not correlate with elevated serum enzyme levels, indicating a low risk of liver-related side effects. However, on rare occasions, sibutramine has been connected to cases of clinically significant acute liver injury.
FDA Approval and Subsequent Withdrawal
The FDA granted approval for sibutramine as an obesity treatment in the United States in 1997. The drug enjoyed widespread prescription until 2010 when emerging research studies demonstrated a concerning association between sibutramine usage and an increased likelihood of experiencing myocardial infarction and stroke. In light of these findings, the drug was officially withdrawn from the market.
Conclusion
While sibutramine once showed promise as a treatment for obesity, concerns about its safety profile, particularly regarding cardiovascular events, led to its removal from clinical use. Its history underscores the importance of continued post-market surveillance for all approved medications.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen